CD34 and carcinoma: Antibody directed against CD31 is still considered the most sensitive and specific marker for endothelial differentiation, being expressed in 90% of angiosarcomas and in slightly more than 1% of carcinomas; the endothelial marker CD34 and the antigen related to factor VIII should also be added to the panel [10,20].